Matches in SemOpenAlex for { <https://semopenalex.org/work/W83045901> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W83045901 endingPage "9" @default.
- W83045901 startingPage "925" @default.
- W83045901 abstract "Multidrug resistance (MDR) is a main reason for paclitaxel (TAX) treatment failure. Indirubin-3'-monoxime (IRO) and Matrine are traditional Chinese medicines, which may reverse the resistance of tumor cells to some chemotherapy drugs, but the relationship between paclitaxel resistance and Matrine is still unclear. The aim of this study was to explore the potential molecular mechanism of IRO and Matrine in reversal of TAX resistance.In this study, MTT assay was used to measure the non-cytotoxic dosage of IRO and Matrine on NCI-H520/TAX25 cells and determine the reversal extent of TAX resistance under non-toxic doses. In addition, RT-PCR and Western blotting were used to evaluate the mRNA expression and the protein level of survivin, Oct-4, and Sox-2 in NCI-H520/TAX25 cells using semi-quantitative methods.There was no obvious inhibition on sensitive cell strains and drug-resistant strains, when the final concentration was at lest 4 µmol/L for IRO and 100 µmol/L for Matrine. So 4 µmol/L of IRO and 100 µmol/L of Matrine were considered as the reversal dosage. When 4 µmol/L of IRO or 100 µmol/L of Matrine were used together with TAX, the sensitivity to TAX increased evidently in NCI-H520/TAX2 cells; the reversal rate of IRO and Matrine was about 1.92 (43.56/22.6 nmol/L) and 1.74 (43.56/25.0 nmol/L), respectively. The mRNA expression and the protein level of survivin, Oct-4, and Sox-2 in NCI-H520/TAX25 decreased significantly (P < 0.05) after addition of IRO or Matrine in TAX treatment, compared to that of TAX treatment alone.The decrease in both mRNA expression and protein level of survivin, Oct-4, and Sox-2 might be the molecular mechanism, by which IRO and Matrine mediate the reversal of TAX resistance." @default.
- W83045901 created "2016-06-24" @default.
- W83045901 creator A5010479257 @default.
- W83045901 creator A5029227356 @default.
- W83045901 creator A5031810848 @default.
- W83045901 creator A5037100270 @default.
- W83045901 creator A5047033918 @default.
- W83045901 creator A5056429685 @default.
- W83045901 creator A5058471307 @default.
- W83045901 creator A5084028248 @default.
- W83045901 date "2013-03-01" @default.
- W83045901 modified "2023-10-16" @default.
- W83045901 title "Molecular mechanism of indirubin-3'-monoxime and Matrine in the reversal of paclitaxel resistance in NCI-H520/TAX25 cell line." @default.
- W83045901 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23489803" @default.
- W83045901 hasPublicationYear "2013" @default.
- W83045901 type Work @default.
- W83045901 sameAs 83045901 @default.
- W83045901 citedByCount "7" @default.
- W83045901 countsByYear W830459012016 @default.
- W83045901 countsByYear W830459012017 @default.
- W83045901 countsByYear W830459012019 @default.
- W83045901 countsByYear W830459012020 @default.
- W83045901 crossrefType "journal-article" @default.
- W83045901 hasAuthorship W83045901A5010479257 @default.
- W83045901 hasAuthorship W83045901A5029227356 @default.
- W83045901 hasAuthorship W83045901A5031810848 @default.
- W83045901 hasAuthorship W83045901A5037100270 @default.
- W83045901 hasAuthorship W83045901A5047033918 @default.
- W83045901 hasAuthorship W83045901A5056429685 @default.
- W83045901 hasAuthorship W83045901A5058471307 @default.
- W83045901 hasAuthorship W83045901A5084028248 @default.
- W83045901 hasConcept C114851261 @default.
- W83045901 hasConcept C126322002 @default.
- W83045901 hasConcept C153911025 @default.
- W83045901 hasConcept C185592680 @default.
- W83045901 hasConcept C190283241 @default.
- W83045901 hasConcept C2775975398 @default.
- W83045901 hasConcept C2776545273 @default.
- W83045901 hasConcept C2776694085 @default.
- W83045901 hasConcept C2777292972 @default.
- W83045901 hasConcept C2780783641 @default.
- W83045901 hasConcept C43617362 @default.
- W83045901 hasConcept C55493867 @default.
- W83045901 hasConcept C71924100 @default.
- W83045901 hasConcept C86803240 @default.
- W83045901 hasConcept C89423630 @default.
- W83045901 hasConcept C98274493 @default.
- W83045901 hasConceptScore W83045901C114851261 @default.
- W83045901 hasConceptScore W83045901C126322002 @default.
- W83045901 hasConceptScore W83045901C153911025 @default.
- W83045901 hasConceptScore W83045901C185592680 @default.
- W83045901 hasConceptScore W83045901C190283241 @default.
- W83045901 hasConceptScore W83045901C2775975398 @default.
- W83045901 hasConceptScore W83045901C2776545273 @default.
- W83045901 hasConceptScore W83045901C2776694085 @default.
- W83045901 hasConceptScore W83045901C2777292972 @default.
- W83045901 hasConceptScore W83045901C2780783641 @default.
- W83045901 hasConceptScore W83045901C43617362 @default.
- W83045901 hasConceptScore W83045901C55493867 @default.
- W83045901 hasConceptScore W83045901C71924100 @default.
- W83045901 hasConceptScore W83045901C86803240 @default.
- W83045901 hasConceptScore W83045901C89423630 @default.
- W83045901 hasConceptScore W83045901C98274493 @default.
- W83045901 hasIssue "5" @default.
- W83045901 hasLocation W830459011 @default.
- W83045901 hasOpenAccess W83045901 @default.
- W83045901 hasPrimaryLocation W830459011 @default.
- W83045901 hasRelatedWork W2352736947 @default.
- W83045901 hasRelatedWork W2355781761 @default.
- W83045901 hasRelatedWork W2356210976 @default.
- W83045901 hasRelatedWork W2373667775 @default.
- W83045901 hasRelatedWork W2376923404 @default.
- W83045901 hasRelatedWork W2392466811 @default.
- W83045901 hasRelatedWork W2616760831 @default.
- W83045901 hasRelatedWork W2985885536 @default.
- W83045901 hasRelatedWork W3030715962 @default.
- W83045901 hasRelatedWork W83045901 @default.
- W83045901 hasVolume "126" @default.
- W83045901 isParatext "false" @default.
- W83045901 isRetracted "false" @default.
- W83045901 magId "83045901" @default.
- W83045901 workType "article" @default.